Myriad Genetics’ (MYGN) “Equal Weight” Rating Reiterated at Stephens

Stephens reaffirmed their equal weight rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note released on Thursday,Benzinga reports. Stephens currently has a $20.00 price objective on the stock.

Several other analysts have also weighed in on the company. Piper Sandler reduced their price objective on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Thursday, January 9th. UBS Group began coverage on shares of Myriad Genetics in a research report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective for the company. Leerink Partners lowered shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Finally, Morgan Stanley lowered their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $23.92.

Myriad Genetics Stock Down 1.0 %

NASDAQ MYGN opened at $12.39 on Thursday. The business has a fifty day moving average price of $14.68 and a two-hundred day moving average price of $21.87. The stock has a market capitalization of $1.13 billion, a PE ratio of -9.53 and a beta of 1.89. Myriad Genetics has a fifty-two week low of $12.17 and a fifty-two week high of $29.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73.

Institutional Trading of Myriad Genetics

Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in Myriad Genetics by 8.3% during the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock worth $128,827,000 after purchasing an additional 359,685 shares during the last quarter. Earnest Partners LLC raised its stake in Myriad Genetics by 3.5% during the second quarter. Earnest Partners LLC now owns 4,072,018 shares of the company’s stock worth $99,602,000 after buying an additional 138,960 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Myriad Genetics by 2.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,776,959 shares of the company’s stock valued at $67,924,000 after buying an additional 75,445 shares during the period. Disciplined Growth Investors Inc. MN boosted its position in Myriad Genetics by 21.1% during the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after acquiring an additional 440,107 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in Myriad Genetics by 5.4% during the 2nd quarter. Sei Investments Co. now owns 2,417,192 shares of the company’s stock worth $59,125,000 after acquiring an additional 124,007 shares during the period. 99.02% of the stock is currently owned by institutional investors.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.